The purpose of this work is to design a clinical trial in collaboration with Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS - Vaccine and Treatment Evaluation Unit (DMID-VTEU) to determine whether PO transition therapy using TMP-SMX is non-inferior to standard of care antimicrobials for uncomplicated pediatric acute hematogenous osteomyelitis. This work will result in DMID Protocol Number: 16-0100 for implementation.